ES2424831B1 - Immunological adjuvant for the formulation of vaccines and Leishmaniasis vaccine that includes it - Google Patents

Immunological adjuvant for the formulation of vaccines and Leishmaniasis vaccine that includes it Download PDF

Info

Publication number
ES2424831B1
ES2424831B1 ES201331159A ES201331159A ES2424831B1 ES 2424831 B1 ES2424831 B1 ES 2424831B1 ES 201331159 A ES201331159 A ES 201331159A ES 201331159 A ES201331159 A ES 201331159A ES 2424831 B1 ES2424831 B1 ES 2424831B1
Authority
ES
Spain
Prior art keywords
vaccine
vaccines
formulation
leishmaniasis
immunological adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201331159A
Other languages
Spanish (es)
Other versions
ES2424831A1 (en
Inventor
Antonio Osuna Carrillo de Albornoz
Teresa Cruz Bustos
Francisco Santoyo González
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Granada
Original Assignee
Universidad de Granada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Granada filed Critical Universidad de Granada
Priority to ES201331159A priority Critical patent/ES2424831B1/en
Publication of ES2424831A1 publication Critical patent/ES2424831A1/en
Priority to PCT/ES2014/070608 priority patent/WO2015011334A1/en
Application granted granted Critical
Publication of ES2424831B1 publication Critical patent/ES2424831B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Adyuvante inmunológico para la formulación de vacunas y vacuna frente a Leishmaniasis que lo comprende.#La presente invención se refiere al uso de compuestos que comprenden una molécula de naturaleza lipídica y un grupo vinil sulfona como adyuvante inmunológico. La molécula lipídica se une a un antígeno para formar un lipopéptido que actúa como vacuna. Además, la presente invención también se refiere a un inmunoadyuvante que comprende dichos compuestos, a una vacuna que comprende estos lipopéptidos, es decir, el compuesto de la invención utilizado como inmunoadyuvante y un antígeno y de forma particular, a la vacuna descrita anteriormente para Leishmaniasis.Immune adjuvant for the formulation of vaccines and Leishmaniasis vaccine comprising it. # The present invention relates to the use of compounds comprising a molecule of a lipid nature and a vinyl sulfone group as an immunological adjuvant. The lipid molecule binds to an antigen to form a lipopeptide that acts as a vaccine. In addition, the present invention also relates to an immunoadjuvant comprising said compounds, to a vaccine comprising these lipopeptides, that is, the compound of the invention used as an immunoadjuvant and an antigen and in particular, to the vaccine described above for Leishmaniasis .

Description

imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

imagen12image12

imagen13image13

imagen14image14

imagen15image15

imagen16image16

imagen17image17

imagen18image18

imagen19image19

imagen20image20

imagen21image21

imagen22image22

Claims (1)

imagen1image 1 imagen2image2 imagen3image3 imagen4image4
ES201331159A 2013-07-26 2013-07-26 Immunological adjuvant for the formulation of vaccines and Leishmaniasis vaccine that includes it Active ES2424831B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201331159A ES2424831B1 (en) 2013-07-26 2013-07-26 Immunological adjuvant for the formulation of vaccines and Leishmaniasis vaccine that includes it
PCT/ES2014/070608 WO2015011334A1 (en) 2013-07-26 2014-07-25 Immunological adjuvant for the formulation of vaccines and leishmaniasis vaccine comprising same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201331159A ES2424831B1 (en) 2013-07-26 2013-07-26 Immunological adjuvant for the formulation of vaccines and Leishmaniasis vaccine that includes it

Publications (2)

Publication Number Publication Date
ES2424831A1 ES2424831A1 (en) 2013-10-08
ES2424831B1 true ES2424831B1 (en) 2014-08-04

Family

ID=49221667

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201331159A Active ES2424831B1 (en) 2013-07-26 2013-07-26 Immunological adjuvant for the formulation of vaccines and Leishmaniasis vaccine that includes it

Country Status (2)

Country Link
ES (1) ES2424831B1 (en)
WO (1) WO2015011334A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930591D0 (en) * 1999-12-23 2000-02-16 Univ London Component for vaccine
BRPI0503187B8 (en) * 2005-05-16 2021-05-25 Univ Rio De Janeiro composition comprising fucose mannose ligand (fml) and saponin, for use as a blocking vaccine against the transmission of canine visceral leishmaniasis

Also Published As

Publication number Publication date
ES2424831A1 (en) 2013-10-08
WO2015011334A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
CL2019003657A1 (en) Antibodies that specifically bind to cd38 useful for enhancing an immune response in a patient. (divisional request 201703275)
CL2018000320A1 (en) Oil based adjuvants (application division 201600650)
BR112013022397A2 (en) vaccines combined with lower doses of antigen and / or adjuvant
CL2017001610A1 (en) Human antibodies to influenza hemagglutinin
CL2018000232A1 (en) Peptide mixture (divisional application 201601405)
PE20170766A1 (en) TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND VARIOUS CANCER ANTIGENS AND METHODS OF USE OF THE SAME
HRP20211451T1 (en) Novel vaccine compositions for porcine epidemic diarrhea virus
EA201790239A1 (en) MOLECULE CARRIER FOR ANTIGENS
EA201691348A1 (en) ONE-FLAKE VACCINE COMPOSITIONS
AR095396A1 (en) ANTIBODY FORMULATIONS
ES2597832T3 (en) Acellular vaccine against pertussis
AR067087A1 (en) VACCINE COMPOSITION AND METHOD TO PREPARE IT
PE20090281A1 (en) LYOPHILIZED ANTIGENIC COMPOSITION
BR112013009164A2 (en) norovirus capsid and rotavirus vp6 protein for use as a combined vaccine.
EA200801251A1 (en) VACCINES AGAINST FLU ADSORBED ON ALUMINUM ADJUVANTS FOR IMMEDIATE ADMISSION
AR092372A1 (en) FORMULATIONS OF LIPOSOMES, USE AND TREATMENT METHOD
AR088907A1 (en) VACCINE
EP2762153A3 (en) Vaccine composition for mucosal administration
BR112017012220A2 (en) processes for preparing an antigen composition and a vaccine, antigen composition, vaccine, uses of an antigen composition and a vaccine, and method for preventing or reducing infection with a swine virus and signs associated with the disease.
AR097683A1 (en) COMPOUNDS AND USE FOR THE PREPARATION OF TAU IMAGE TRAINING AGENTS AND FORMULATIONS FOR TAU IMAGE FORMATION
ES2424831B1 (en) Immunological adjuvant for the formulation of vaccines and Leishmaniasis vaccine that includes it
PH12014502015A1 (en) Novel veterinary vaccine
AR093341A1 (en) CHEMICAL VACCINAL ANTIGENS AGAINST HEPATITIS C VIRUS
BR112014023283A8 (en) IMMUNOGENIC COMPOSITION, SECOND IMMUNOGENIC COMPOSITION, AND METHOD FOR PREVENTION AND/OR TREATMENT AGAINST INFLUENZA DISEASE
EA201200538A1 (en) ARABINOGALAKTAN TO IMPROVE ACQUIRED IMMUNE RESPONSE

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2424831

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20140804